- Home
- KPTI vs APT Comparison
KPTI vs APT Comparison
Compare KPTI & APT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- APT
- Stock Information
- Founded
- KPTI 2008
- APT 1983
- Country
- KPTI United States
- APT Canada
- Employees
- KPTI N/A
- APT N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- APT
- Sector
- KPTI Health Care
- APT
- Exchange
- KPTI Nasdaq
- APT Nasdaq
- Market Cap
- KPTI 44.5M
- APT 50.5M
- IPO Year
- KPTI 2013
- APT 1995
- Fundamental
- Price
- KPTI $5.92
- APT $4.61
- Analyst Decision
- KPTI Buy
- APT
- Analyst Count
- KPTI 6
- APT 0
- Target Price
- KPTI $39.80
- APT N/A
- AVG Volume (30 Days)
- KPTI 221.8K
- APT 21.2K
- Earning Date
- KPTI 08-11-2025
- APT 08-07-2025
- Dividend Yield
- KPTI N/A
- APT N/A
- EPS Growth
- KPTI N/A
- APT N/A
- EPS
- KPTI N/A
- APT 0.33
- Revenue
- KPTI $137,269,000.00
- APT $58,562,000.00
- Revenue This Year
- KPTI $2.18
- APT N/A
- Revenue Next Year
- KPTI $11.28
- APT N/A
- P/E Ratio
- KPTI N/A
- APT $14.03
- Revenue Growth
- KPTI N/A
- APT N/A
- 52 Week Low
- KPTI $3.51
- APT $4.06
- 52 Week High
- KPTI $16.95
- APT $6.44
- Technical
- Relative Strength Index (RSI)
- KPTI 72.07
- APT 41.28
- Support Level
- KPTI $3.65
- APT $4.62
- Resistance Level
- KPTI $4.35
- APT $4.78
- Average True Range (ATR)
- KPTI 0.50
- APT 0.14
- MACD
- KPTI 0.17
- APT -0.03
- Stochastic Oscillator
- KPTI 70.06
- APT 15.89
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About APT Alpha Pro Tech Ltd.
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.